Details of Disease

Disease Name

Skin burns

Disease Class

ME65: Skin sensation disturbance

Disease Hierarchy

DIS01GPL: Grass pollen hypersensitivity

DISEQX10: Skin burns

ICD-11

ICD-11: ME65.0

General Information of Disease (ID: DISEQX10)

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 6 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Anacaulase	DM1L7SH	Approved	NA	[1]
Collagenase	DMFJ2OG	Approved	NA	[2]
INTEGRA Artificial Skin	DM1552V	Approved	NA	[2]
Nitrofurazone	DMSM2KE	Approved	Small molecular drug	[2]
Sodium chloride	DMM3950	Approved	Small molecular drug	[2]
Sutilains	DM83OH8	Approved	NA	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

This Disease is Treated as An Indication in 3 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Recombinant acidic fibroblast growth factor	DM8HVNR	Phase 3	NA	[3]
Skin tissue replacement therapy	DMH20G2	Phase 1/2	NA	[1]
EUK-189	DMY9ZAS	Phase 1	Small molecular drug	[4]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 1 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PV-707	DMRODZS	Discontinued in Phase 2	NA	[5]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 1 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
INP-341	DMD6H21	Preclinical	NA	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	Pharmacokinetic Properties of 2nd-Generation Fibroblast Growth Factor-1 Mutants for Therapeutic Application. November 1, 2012.
4	Evaluation of EUK-189, a synthetic superoxide dismutase/catalase mimetic as a radiation countermeasure. Immunopharmacol Immunotoxicol. 2008;30(2):271-90.
5	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016102)
6	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030570)